Copyright
©2011 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Oct 7, 2011; 17(37): 4166-4173
Published online Oct 7, 2011. doi: 10.3748/wjg.v17.i37.4166
Published online Oct 7, 2011. doi: 10.3748/wjg.v17.i37.4166
Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease
Kara Bradford, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, United States
David Q Shih, Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, United States
Author contributions: Bradford K and Shih DQ solely contributed to this paper.
Supported by Grant from Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center
Correspondence to: David Q Shih, MD, PhD, Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Suite 4066, Los Angeles, CA 90048, United States. david.shih@csmc.edu
Telephone: +1-310-4237722 Fax: +1-310-4230224
Received: March 22, 2011
Revised: June 20, 2011
Accepted: June 27, 2011
Published online: October 7, 2011
Revised: June 20, 2011
Accepted: June 27, 2011
Published online: October 7, 2011
Core Tip